Guest: Edward S. Kim, MD

For those non-small cell lung cancer (NSCLC) patients without driver mutations or PD-L expressions, the new care paradigm brought on by KEYNOTE-189 has shown to improve these patients’ progression-free survival rates. Here to break down this clinical trial’s unprecedented findings is Dr. Edward Kim, Chair of Solid Tumor Oncology and Investigational Therapeutics at Levine Cancer Institute.

Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.